PTPA and acute myeloid leukemia: Thus FLT3-ITD+ AML patients have lower PP2A activity, higher pY307-PP2Ac, and lower PP2A-A expression than WT-FLT3 patients, suggesting that PP2A inhibition may be clinically important in FLT3-ITD+ AML.